AOD-9604: The C-Terminal Fragment of HGH and Fat Metabolism Research
Research Use Only. This article is for scientific and educational reference only. All products are sold for research purposes and are not intended for human or animal consumption.
# AOD-9604: The C-Terminal Fragment of HGH and Fat Metabolism Research
For Research Purposes Only — Not Intended for Human or Animal Consumption
Introduction
AOD-9604 (Anti-Obesity Drug 9604) is a synthetic peptide corresponding to amino acids 177-191 of human growth hormone (hGH), with an additional tyrosine residue at the N-terminus. It was developed by researchers at Monash University in Australia and subsequently commercialized by Metabolic Pharmaceuticals, which conducted a Phase III clinical trial program before discontinuing development.
The compound represents an attempt to isolate the lipolytic (fat-burning) activity of growth hormone from its growth-promoting and insulin-desensitizing effects — a pharmacological separation that, if achievable, would have significant implications for obesity treatment.
The GH Lipolytic Domain
Human growth hormone has multiple biological activities mediated through different structural domains. The growth-promoting effects (IGF-1 stimulation, protein synthesis) are mediated primarily through the GH receptor (GHR) binding domains in the N-terminal region of the molecule.
The lipolytic effects of GH — stimulation of fat breakdown in adipose tissue — were proposed to be mediated through a distinct C-terminal region. Ng et al. (2000) at Monash University demonstrated that the C-terminal fragment corresponding to amino acids 177-191 of hGH retained lipolytic activity in adipocytes while lacking the growth-promoting effects of full-length GH.
This observation formed the basis for AOD-9604 development: a peptide that could stimulate lipolysis without the adverse effects of full-length GH (insulin resistance, acromegaly risk, IGF-1-mediated proliferative effects).
Mechanism of Lipolytic Action
The mechanism by which AOD-9604 stimulates lipolysis is not fully characterized, but published research has identified several relevant findings:
Beta-3 adrenergic receptor involvement: Heffernan et al. (2001) demonstrated that AOD-9604's lipolytic effects in mice were partially blocked by beta-3 adrenergic receptor antagonists, suggesting involvement of this receptor in the lipolytic mechanism. Beta-3 adrenergic receptors are expressed primarily in adipose tissue and mediate catecholamine-stimulated lipolysis.
cAMP-dependent lipolysis: AOD-9604 appears to stimulate cAMP production in adipocytes, activating protein kinase A (PKA) and hormone-sensitive lipase (HSL) — the primary enzyme responsible for triglyceride hydrolysis in adipose tissue.
Absence of GHR binding: Critically, AOD-9604 does not bind to the GH receptor with significant affinity, explaining its lack of growth-promoting and insulin-desensitizing effects. This receptor selectivity is the key pharmacological feature that distinguishes AOD-9604 from full-length GH.
Animal Studies
Preclinical studies in obese mice demonstrated that AOD-9604 administration reduced body fat without affecting food intake, lean body mass, or insulin sensitivity. Ng et al. (2000) reported that daily AOD-9604 injections in obese mice produced significant reductions in body weight and fat mass over 8 weeks, with effects comparable to full-length GH but without the insulin resistance associated with GH treatment.
Clinical Trial Program
Metabolic Pharmaceuticals conducted a Phase III clinical trial program for AOD-9604 in obese adults. The primary endpoint was weight loss over 24 weeks.
The Phase III results were disappointing: AOD-9604 did not produce statistically significant weight loss compared to placebo in the primary endpoint analysis. The trial enrolled approximately 300 obese adults and used doses of 1 mg/day administered subcutaneously.
The failure of the Phase III trial led Metabolic Pharmaceuticals to discontinue the obesity indication, though the compound subsequently received GRAS (Generally Recognized As Safe) status from the FDA for use as a food ingredient — a regulatory classification that reflects its safety profile rather than efficacy.
Post-Trial Research
Following the discontinuation of the obesity program, research interest in AOD-9604 shifted toward other potential applications, including cartilage and bone repair. Preclinical studies have examined AOD-9604's effects on chondrocyte function and osteoarthritis models, with some positive findings, though this research is at an early stage.
Interpretation of the Evidence
The AOD-9604 story illustrates the challenge of translating promising preclinical findings to clinical efficacy. The robust lipolytic effects in obese mice did not translate to meaningful weight loss in humans at the doses studied. This translational failure may reflect species differences in adipose tissue biology, differences in the relative contribution of GH-mediated lipolysis to overall energy balance, or dose-response differences between rodents and humans.
References
- Ng, F.M., et al. (2000). Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone. Hormone Research, 53(6), 274–278.
- Heffernan, M.A., et al. (2001). The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta(3)-AR knock-out mice. Endocrinology, 142(12), 5182–5189.